PHAR vs ERAS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

PHAR

39.9
AI Score
VS
ERAS Wins

ERAS

45.1
AI Score

Investment Advisor Scores

PHAR

40score
Recommendation
AVOID NEW MONEY

ERAS

45score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric PHAR ERAS Winner
Forward P/E 212.766 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -3.2% 0.0% ERAS
Earnings Growth -62.9% 0.0% ERAS
Tradestie Score 39.9/100 45.1/100 ERAS
Profit Margin 2.5% 0.0% PHAR
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD ERAS

Relative Price Performance (Last 90 Days)

PHAR 1M: -0.9% · 3M: -15.4% ERAS 1M: +0.7% · 3M: -26.5%

Current Technical Phase

PHAR

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 58.1 · Price: $10.67

ERAS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.3%), weak momentum, RSI 43

RSI (14): 42.7 · Price: $14.04

Fundamentals Snapshot

Metric PHAR ERAS
Market Cap — —
Forward P/E 162.9 -22.5
Trailing P/E 74.2 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.9% —
Operating Margin 0.0% 0.0%
EPS 0.13 -0.95
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ERAS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.